Comparative Pharmacology
Head-to-head clinical analysis: LYPQOZET versus MELLARIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LYPQOZET versus MELLARIL.
LYPQOZET vs MELLARIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LYPQOZET is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin at the presynaptic serotonin transporter, leading to increased synaptic levels of serotonin.
Thioridazine is a phenothiazine antipsychotic that blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors, and also blocks alpha-adrenergic receptors, histamine H1 receptors, and muscarinic M1 receptors.
Oral, 75 mg once daily.
Typical adult dose: 10-25 mg orally 3 times daily. Maximum dose: 200 mg/day.
None Documented
None Documented
Terminal elimination half-life is 22-28 hours in adults, allowing once-daily dosing. Extended half-life supports sustained therapeutic levels.
Terminal elimination half-life 21-24 hours; steady-state achieved within 5-7 days
Primarily renal (75% unchanged) and fecal/biliary (20% as metabolites); <5% unchanged in feces.
Primarily renal (70-80% as metabolites, <1% unchanged); biliary/fecal (20-30%)
Category C
Category C
Antipsychotic
Antipsychotic